Skip to main content
SpringerLink
Log in

Maintenance of remission in Crohn’s disease

  • Chapter
Trends in Inflammatory Bowel Disease Therapy 1999

  • 73 Accesses

Abstract

Flares of Crohn’s disease can be controlled in 50-70% of the patients within 8-12 weeks of start of therapy. Relapses upon discontinuation of therapy, however, are frequent and most patients will receive maintenance therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Summers RW, Switz DM, Sessions JT Jr et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1979;77:847–69.

    PubMed  CAS  Google Scholar 

  2. Malchow H, Ewe K, Brandes JW et al. European Co-operative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249–66.

    PubMed  CAS  Google Scholar 

  3. Messori A, Brignola C, Trallori G et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn’s disease: a meta-analysis. Am J Gastroenterol 1994;89:692–8.

    PubMed  CAS  Google Scholar 

  4. Steinhart AH, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for the maintenance therapy of Crohn’s disease: a meta-analysis. Am J Gastroenterol 1994;89:2116–24.

    PubMed  CAS  Google Scholar 

  5. Hanauer SB, Krawitt EL, Robinson M, Rick GG, Safdi MA and the Pentasa Crohn’s Disease Compassionate Use Study Group. Long term management of Crohn’s disease with mesalamine capsules (Pentasa). Am J Gastroenterol 1993;88:1343–50.

    PubMed  CAS  Google Scholar 

  6. Modigliani R, Colombel JF, Dupas JL et al., for GETAID. Mesalamine in Crohn’s disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance. Gastroenterology 1996;110:688–93.

    Article  PubMed  Google Scholar 

  7. Greenberg GR, Feagan BG, Martin F et al. and the Canadian IBD group. Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled, dose-ranging study. Gastroenterology 1996;110:45–51.

    Article  PubMed  Google Scholar 

  8. Löfberg R, Rutgeerts P, Malchow H et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn’s disease: a placebo-controlled one-year study. Gut 1996;39:82–6.

    Article  PubMed  Google Scholar 

  9. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn’s disease: a meta-analysis. Ann Intern Med 1995;122:132–42.

    Google Scholar 

  10. . O’Donoghue DP, Dawson AM, Powell-Tuck J, Bown RL, Lennard-Jones JE. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn’s disease. Lancet 1978;2:955-7.

    Article  PubMed  Google Scholar 

  11. Bouhnik Y, Lémann M, Mary JY et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347:215–19.

    Article  PubMed  CAS  Google Scholar 

  12. Rutgeerts P, D’Haens G, van Deventer SJH et al. Retreatment with anti-TNFa chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn’s disease. Gastroenterology 1997;112:A1078.

    Article  Google Scholar 

  13. Belluzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation in relapses in Crohn’s disease. N Engl Med 1996;334:1557–60.

    Article  Google Scholar 

  14. Lorenz-Meyer H, Bauer P, Nicolay C et al. and study group members of the German Crohn’s Disease Study Group. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn’s disease. Scand J Gastroenterol 1996;31:778–85.

    Article  PubMed  CAS  Google Scholar 

  15. Lee ECG, Papainannou N. Recurrence following surgery for Crohn’s disease. Clin Gastroenterol 1980;9:419–38.

    PubMed  CAS  Google Scholar 

  16. Rutgeerts P, Geboes K, Vantrappen G. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25:665–72.

    Article  PubMed  CAS  Google Scholar 

  17. Sankey EA, Dhillon AP, Anthony A et al. Early mucosal changes in Crohn’s disease. Gut 1993;34:375–81.

    Article  PubMed  CAS  Google Scholar 

  18. Rutgeerts P, Geboes K. Inflammatory bowel disease — Crohn’s disease and pre-aphthoid lesions. Lancet 1993;341:1443–4.

    Article  PubMed  CAS  Google Scholar 

  19. Lescut D, Vanco D, Bonnière P et al. Perioperative endoscopy of the whole small bowel in Crohn’s disease. Gut 1993;34:647–9.

    Article  PubMed  CAS  Google Scholar 

  20. Lescut D, Vanco D, Colombel JF et al. Influence des lésions endoscopiques d’amont sur les lésions endoscopiques anastomatiques au cours de la maladie de Crohn. Gastroenterol Clin Biol 1990;14:A20.

    Google Scholar 

  21. Olaison G, Smedh K, Sjödahl R. Natural course of Crohn’s disease after ileocolic resection: endoscopically visualized ileal ulcers preceding symptoms. Gut 1992;33:331–5.

    Article  PubMed  CAS  Google Scholar 

  22. Rutgeerts P, Geboes K, Vantrappen G et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990;99:450–63.

    Google Scholar 

  23. D’Haens GR, Gasparaitis AE, Hanauer SB. The length of recurrent ileitis after ileocolonic resection correlates with presurgical extent of Crohn’s disease. Gastroenterology 1993;104:A692.

    Google Scholar 

  24. Sachar DB, Andrews HA, Farmer RG et al. Proposed classification of patient subgroups in Crohn’s disease. Gastroenterol Int 1992;5:141–54.

    Google Scholar 

  25. Pallone F, Boivirant M, Antonietta M, Cosintino R, Pranthera C, Torsoli A. Analysis of clinical course of postoperative recurrence in Crohn’s disease of distal ileum. Dig Dis Sci 1992;37:215–19.

    Article  PubMed  CAS  Google Scholar 

  26. Smedh K, Olaison G, Sjödahl R. Initiation of anastomotic recurrence of Crohn’s disease after ileocolic resection. Onset proximal to the junction and preceded by increased phospholipase A2 activity. Scand J Gastroenterol 1992;27:691–4.

    Article  PubMed  CAS  Google Scholar 

  27. Rutgeerts P, Geboes K, Peeters M et al. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet 1991;338:771–4.

    Article  PubMed  CAS  Google Scholar 

  28. Cameron JL, Hamilton SR, Coleman J et al. Patterns of ileal recurrence in Crohn’s disease. A prospective randomized study. Ann Surg 1992;215:546–52.

    Article  PubMed  CAS  Google Scholar 

  29. Rutgeerts P, Hiele M, Geboes K et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995;108:1617–21.

    Article  PubMed  CAS  Google Scholar 

  30. Ewe K, Herfarth C, Malchow H et al. Postoperative recurrence of Crohn’s disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion 1989;42:224–32.

    Article  PubMed  CAS  Google Scholar 

  31. Caprilli R, Andreoli A, Capurso L et al. Oral 5-aminosalicylic acid (Asacol) for prevention of Crohn’s disease postoperative recurrences. Aliment Pharmacol Ther 1994;8:35–43.

    Article  PubMed  CAS  Google Scholar 

  32. Brignola C, Cottone M, Pera A et al. Mesalamine in the prevention of endoscopie recurrence after intestinal resection for Crohn’s disease. Gastroenterology 1995;108:345–9.

    Article  PubMed  CAS  Google Scholar 

  33. Florent Ch, Cortot A, Quandale P et al. Placebo-controlled trial of ClaversalR(C) in the prevention of early endoscopie relapse after `curative’ resection for Crohn’s disease. Gastroenterology 1992;102:A623.

    Google Scholar 

  34. Fiasse R, Fontaine F, Vanheuverzwyn R. Prevention of Crohn’s disease recurrences after intestinal resection with Eudragit-L-coated 5-aminosalicylic acid. Preliminary results of a one-year double-blind placebo controlled study. Gastroenterology 1991;100:A208.

    Google Scholar 

  35. McLeod RS, Wolff BG, Steinhart AH et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn’s disease. Gastroenterology 1995;109:404–13.

    Article  PubMed  CAS  Google Scholar 

  36. Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P and the ECCDS VI Study Group. Prophylaxis of postoperative relapse in Crohn’s disease with mesalazine (Pentasa®) in comparison with placebo. Gastroenterology 1997;112:A1027.

    Google Scholar 

  37. Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn’s disease: a metaanalysis adjusted for confounding variables. Gastroenterology 1997;113:1465–73.

    Article  PubMed  CAS  Google Scholar 

  38. Hellers G, Löfberg R, Rutgeerts P et al. Oral budesonide for prevention of recurrence following ileocolonic resection of Crohn’s disease. A one year placebo-controlled study. Gastroenterology 1996;110:A923.

    Google Scholar 

  39. Adler DJ, Korelitz BI. The long-term efficacy of 6-mercaptopurine in the treatment of inflammatory bowel disease. In: MacDermott RP, editor. Inflammatory Bowel Disease: Current Status and Future Approach. New York: Elsevier; 1991:731–35.

    Google Scholar 

  40. Korelitz B, Hanauer S, Rutgeerts P, Present D, Peppercorn M. Postoperative prophylaxis with 6-MP, 5-ASA or placebo in Crohn’s disease: a 2 year multicenter trial. Gastroenterology 1998;114:G4141.

    Article  Google Scholar 

Download references

Authors
  1. P. Rutgeerts
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Gastroenterology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada

    C. N. Williams

  2. Faculty of Medicine, The Health Sciences Centre, Memorial University of Newfoundland, St John’s, Newfoundland, Canada

    R. F. Bursey

  3. Faculty of Medicine, The University of Calgary, Alberta, Canada

    D. G. Gall , L. R. Sutherland  & J. L. Wallace ,  & 

  4. University of Montreal, Canada

    F. Martin

  5. Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

    R. S. McLeod

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Rutgeerts, P. (2000). Maintenance of remission in Crohn’s disease. In: Williams, C.N., et al. Trends in Inflammatory Bowel Disease Therapy 1999. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4002-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-4002-7_14

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-5769-1

  • Online ISBN: 978-94-011-4002-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation